Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1980 2
1985 1
1986 2
1987 2
1988 2
1989 3
1990 2
1991 3
1992 3
1993 9
1994 18
1995 9
1996 21
1997 20
1998 24
1999 25
2000 32
2001 39
2002 56
2003 52
2004 67
2005 71
2006 67
2007 81
2008 117
2009 137
2010 164
2011 186
2012 255
2013 259
2014 303
2015 309
2016 398
2017 409
2018 439
2019 563
2020 612
2021 687
2022 568
2023 4
Text availability
Article attribute
Article type
Publication date

Search Results

5,372 results
Results by year
Filters applied: . Clear all
Page 1
Dupilumab in Children with Uncontrolled Moderate-to-Severe Asthma.
Bacharier LB, Maspero JF, Katelaris CH, Fiocchi AG, Gagnon R, de Mir I, Jain N, Sher LD, Mao X, Liu D, Zhang Y, Khan AH, Kapoor U, Khokhar FA, Rowe PJ, Deniz Y, Ruddy M, Laws E, Patel N, Weinreich DM, Yancopoulos GD, Amin N, Mannent LP, Lederer DJ, Hardin M; Liberty Asthma VOYAGE Investigators. Bacharier LB, et al. Among authors: mao x. N Engl J Med. 2021 Dec 9;385(24):2230-2240. doi: 10.1056/NEJMoa2106567. N Engl J Med. 2021. PMID: 34879449 Clinical Trial.
TRIP12 ubiquitination of glucocerebrosidase contributes to neurodegeneration in Parkinson's disease.
Seo BA, Kim D, Hwang H, Kim MS, Ma SX, Kwon SH, Kweon SH, Wang H, Yoo JM, Choi S, Kwon SH, Kang SU, Kam TI, Kim K, Karuppagounder SS, Kang BG, Lee S, Park H, Kim S, Yan W, Li YS, Kuo SH, Redding-Ochoa J, Pletnikova O, Troncoso JC, Lee G, Mao X, Dawson VL, Dawson TM, Ko HS. Seo BA, et al. Among authors: mao x. Neuron. 2021 Dec 1;109(23):3758-3774.e11. doi: 10.1016/j.neuron.2021.09.031. Epub 2021 Oct 12. Neuron. 2021. PMID: 34644545
Long-term safety and efficacy of dupilumab in patients with moderate-to-severe asthma (TRAVERSE): an open-label extension study.
Wechsler ME, Ford LB, Maspero JF, Pavord ID, Papi A, Bourdin A, Watz H, Castro M, Nenasheva NM, Tohda Y, Langton D, Cardona G, Domingo C, Park HS, Chapman KR, Mao X, Zhang Y, Khan AH, Deniz Y, Rowe PJ, Kapoor U, Khokhar FA, Mannent LP, Ruddy M, Laws E, Amin N, Hardin M. Wechsler ME, et al. Among authors: mao x. Lancet Respir Med. 2022 Jan;10(1):11-25. doi: 10.1016/S2213-2600(21)00322-2. Epub 2021 Sep 28. Lancet Respir Med. 2022. PMID: 34597534 Clinical Trial.
Neuronal NLRP3 is a parkin substrate that drives neurodegeneration in Parkinson's disease.
Panicker N, Kam TI, Wang H, Neifert S, Chou SC, Kumar M, Brahmachari S, Jhaldiyal A, Hinkle JT, Akkentli F, Mao X, Xu E, Karuppagounder SS, Hsu ET, Kang SU, Pletnikova O, Troncoso J, Dawson VL, Dawson TM. Panicker N, et al. Among authors: mao x. Neuron. 2022 Aug 3;110(15):2422-2437.e9. doi: 10.1016/j.neuron.2022.05.009. Epub 2022 Jun 1. Neuron. 2022. PMID: 35654037
Structural basis of SARM1 activation, substrate recognition, and inhibition by small molecules.
Shi Y, Kerry PS, Nanson JD, Bosanac T, Sasaki Y, Krauss R, Saikot FK, Adams SE, Mosaiab T, Masic V, Mao X, Rose F, Vasquez E, Furrer M, Cunnea K, Brearley A, Gu W, Luo Z, Brillault L, Landsberg MJ, DiAntonio A, Kobe B, Milbrandt J, Hughes RO, Ve T. Shi Y, et al. Among authors: mao x. Mol Cell. 2022 May 5;82(9):1643-1659.e10. doi: 10.1016/j.molcel.2022.03.007. Epub 2022 Mar 24. Mol Cell. 2022. PMID: 35334231 Free article.
5,372 results